Crinetics Pharmaceuticals SEC Filings

Crinetics Pharmaceuticals (CRNX) reported Q3 2025 results and its first FDA approval. The FDA approved PALSONIFY (paltusotine) on September 25, 2025 for adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. The quarter did not include product sales.

Revenue was $143 thousand, primarily from a Japan license. Operating expenses rose with commercialization and pipeline spend: research and development $90.5 million and selling, general and administrative $52.3 million. Net loss was $130.1 million (basic and diluted loss per share $1.38), compared with a $76.8 million loss a year ago. Other income was $12.5 million, reflecting interest on investments.

Cash, cash equivalents and investment securities totaled $1.09 billion as of September 30, 2025, and management believes this is sufficient for at least 12 months. The company advanced atumelnant in CAH and ADCS and prepared an SST2-targeted NDC (CRN09682) Phase 1/2 start. Shares outstanding were 94,891,840 as of October 28, 2025.

Crinetics Pharmaceuticals (CRNX) reported an insider transaction by its Chief Medical and Development Officer. On November 3, 2025, the officer exercised 5,000 stock options at an exercise price of $16.89 per share and, on the same date, sold 4,900 shares at a volume‑weighted average price of $42.65 (price range $42.14–$43.09) and 100 shares at $43.27.

The sales were effected pursuant to a Rule 10b5‑1 trading plan adopted on May 21, 2025. Following the transactions, the officer directly beneficially owned 66,270 shares of common stock. Derivative securities beneficially owned following the transactions were 74,042 stock options. The option grant vests 25% on September 30, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to continued employment.

Crinetics Pharmaceuticals (CRNX) reporting person Dana Pizzuti executed option exercises and open-market sales on 10/01/2025. The Form 4 shows a stock option exercise for 5,000 shares at an exercise price of $16.89, creating 5,000 underlying shares. The same day, 5,000 shares were sold in open-market transactions under a Rule 10b5-1 trading plan at a volume-weighted average price of $41.81 (range $41.34–$42.16). Following the reported transactions, the reporting person directly owned 66,270 shares. The filer corrected a prior Form 4 that had misstated post-transaction ownership as 96,270 shares; the correction clarifies the true direct ownership.

Form 144 notice for Crinetics Pharmaceuticals, Inc. (CRNX) shows a proposed sale related to an insider option exercise and subsequent planned sale. The filer reports acquisition of 5,000 common shares on 10/01/2025 via exercise of stock options and indicates an intended sale of those 5,000 shares on 10/01/2025 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $208,250.00. The filing lists 94,175,994 shares outstanding. Recent disclosed 10b5-1 sales by the same person, Dana Pizzuti, include sales on 09/02/2025 (5,000 shares, $160,515), 08/22/2025 (30,000 shares, $912,999), and 08/20/2025 (6,492 shares, $189,426.82). The form includes the standard representation that the seller does not possess undisclosed material adverse information and references reliance on a Rule 10b5-1 plan where applicable.

Crinetics Pharmaceuticals insider sale by President & CEO Richard S. Struthers. The filing reports that on 09/26/2025 Mr. Struthers sold 4,000 shares of common stock in open-market transactions at $45.00 per share under a Rule 10b5-1 trading plan adopted August 30, 2024. The Form 4 lists his post-transaction beneficial holdings across direct and indirect holdings, including 320,017 shares held directly and multiple indirect holdings via family trusts and spouse (for example, 661,205 shares by Family Trust 1 and 106,000 shares indirect by Family Trust 2). The sale was effected automatically under the trading plan and was signed by an attorney-in-fact on 09/30/2025.

Crinetics Pharmaceuticals director Matthew K. Fust reported transactions on 09/26/2025. He exercised 10,000 stock options with a $1.91 exercise price and acquired 10,000 shares, and sold 16,000 shares in open-market transactions at $44.75 per share executed under a Rule 10b5-1 trading plan. After these transactions he beneficially owned 22,836 shares of common stock and held 10,000 stock options (with 2,092 derivative securities reported as beneficially owned following the transactions). The 10,000 options became exercisable per the stated vesting schedule; 1/3 vested on 02/16/2019 with monthly vesting thereafter.

Crinetics Pharmaceuticals (CRNX) filed a Form 144 notifying a proposed sale of 16,000 common shares through Morgan Stanley Smith Barney LLC on 09/26/2025 with an aggregate market value of $574,240.00. The filing shows the shares were acquired as 10,000 via exercise of stock options on 09/26/2025 (paid in cash) and 6,000 as restricted stock units on 06/07/2024. The company reports 94,175,994 shares outstanding and discloses no securities sold by the reporting person in the past three months. The filer certifies they are unaware of any undisclosed material adverse information.

Crinetics Pharmaceuticals, Inc. (CRNX) submitted a Form 144 notice for the proposed sale of securities. The filer intends to sell 4,000 shares of Common stock through UBS Financial Services Inc. (11 Madison Ave, New York) with an aggregate market value of $180,000. The approximate date of sale is 09/26/2025 on NASDAQ. The shares were acquired as Founder Shares from the issuer on 07/31/2011, and full payment was recorded on that date. The filing reports nothing to report for securities sold during the past three months. Other standard notice fields (such as a signed date of notice) are present as headers but no explicit signature date or contact details are provided in the text supplied.